+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study



Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study



Clinical Microbiology and Infection 21(12): 1106.E1-8



The increasing prevalence of colistin resistance (ColR) Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (Kp) is a matter of concern because of its unfavourable impact on mortality of KPC-Kp bloodstream infections (BSI) and the shortage of alternative therapeutic options. A matched case-control-control analysis was conducted. The primary study end point was to assess risk factors for ColR KPC-Kp BSI. The secondary end point was to describe mortality and clinical characteristics of these infections. To assess risk factors for ColR, 142 patients with ColR KPC-Kp BSI were compared to two controls groups: 284 controls without infections caused by KPC-Kp (control group A) and 284 controls with colistin-susceptible (ColS) KPC-Kp BSI (control group B). In the first multivariate analysis (cases vs. group A), previous colistin therapy, previous KPC-Kp colonization, ≥3 previous hospitalizations, Charlson score ≥3 and neutropenia were found to be associated with the development of ColR KPC-Kp BSI. In the second multivariate analysis (cases vs. group B), only previous colistin therapy, previous KPC-Kp colonization and Charlson score ≥3 were associated with ColR. Overall, ColR among KPC-Kp blood isolates increased more than threefold during the 4.5-year study period, and 30-day mortality of ColR KPC-Kp BSI was as high as 51%. Strict rules for the use of colistin are mandatory to staunch the dissemination of ColR in KPC-Kp-endemic hospitals.

(PDF emailed within 0-6 h: $19.90)

Accession: 058778230

Download citation: RISBibTeXText

PMID: 26278669

DOI: 10.1016/j.cmi.2015.08.001


Related references

Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. Journal of Clinical Microbiology 48(6): 2271-2274, 2010

Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. International Journal of Infectious Diseases 12(6): 653-659, 2008

Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study. Infection 41(1): 61-67, 2013

Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period. Diagnostic Microbiology and Infectious Disease 92(3): 235-240, 2018

Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections. Antimicrobial Agents and ChemoTherapy 58(10): 5732-5735, 2015

Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. Journal of Antimicrobial ChemoTherapy 60(5): 1124-1130, 2007

Risk factors and clinical evolution of carbapenemase-producing Klebsiella pneumoniae infections in a university hospital in Spain. Case-control study. Revista Espanola de Quimioterapia 31(5): 427-434, 2018

In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. Journal of Antimicrobial ChemoTherapy 69(7): 1856-1865, 2015

Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. Journal of Antimicrobial ChemoTherapy 66(6): 1383-1391, 2011

Evaluation of risk factors for colistin resistance among uropathogenic isolates of Escherichia coli and Klebsiella pneumoniae: a case-control study. Journal of Medical Microbiology 2019, 2019

Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum -lactamase-producing Klebsiella pneumoniaeA casea“control study. 2009

Epidemiology and risk factors for ESBL-producing Klebsiella pneumoniae: a case control study. Journal of Infection in Developing Countries 4(11): 717-722, 2011

Risk factors for in-hospital mortality among adult patients infected with colistin-resistant carbapenemase producing Klebsiella pneumoniae: a retrospective cohort study. Revista Chilena de Infectologia 35(3): 239-245, 2018

Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial ChemoTherapy 71(11): 3242-3249, 2016

A Multi-Centered Case-Case-Control Study of Factors Associated with Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Infections in Children and Young Adults. Pediatric Infectious Disease Journal 2018, 2018